CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer

Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer

(2020) Oscar Arrieta et al.   Cancer Medicine

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

(2020) Wenting Zhang et al.   Frontiers in Immunology

Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC

(2020) Annunziata Nigro et al.   Frontiers in Immunology

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

(2019) Branimir I. Sikic et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging therapies for non-small cell lung cancer

(2019) Chao Zhang et al.   Journal of Hematology & Oncology

High expression of CD47 in triple negative breast cancer is associated with epithelial‑mesenchymal transition and poor prognosis

(2019) Jingping Yuan et al.   Oncology Letters

Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients

(2019) Jingping Yuan et al.   Cancer Cell International

The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors

(2019) Emmanouil Tzatzarakis et al.   Expert Review of Anticancer Therapy

Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer

(2019) Xuyao Zhang et al.   Journal for ImmunoTherapy of Cancer

The MYC oncogene is a global regulator of the immune response

(2018) Stephanie C. Casey et al.   BLOOD

Prognostic significance of CD47 in human malignancies: a systematic review and meta-analysis

(2018) Hui-Jun Zhao et al.   Translational Cancer Research

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The contribution of cross-talk between the cell-surface proteins CD36 and CD47–TSP-1 in osteoclast formation and function

(2018) Srinivas V. Koduru et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Programmed cell removal by calreticulin in tissue homeostasis and cancer

(2018) Mingye Feng et al.   Nature Communications

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

(2018) Ranjana Advani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer

(2017) Paola A. Betancur et al.   Nature Communications

Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non–Small Cell Lung Cancer

(2017) Xuyao Zhang et al.   Cancer Immunology Research

Targeting CD47: the achievements and concerns of current studies on cancer immunotherapy

(2017) Yuting Huang et al.   Journal of Thoracic Disease

Calreticulin Expression in Human Non–Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis

(2016) Jitka Fucikova et al.   CANCER RESEARCH

CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer

(2016) Hui Zhao et al.   Scientific Reports

HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells

(2015) Huimin Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients

(2015) Irène Baccelli et al.   Oncotarget

The CD47–SIRPα pathway in cancer immune evasion and potential therapeutic implications

(2012) Mark P Chao et al.   CURRENT OPINION IN IMMUNOLOGY

Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells

(2012) D Kim et al.   LEUKEMIA

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

(2012) S. B. Willingham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy

(2011) M. P. Chao et al.   BLOOD

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma

(2010) Mark P. Chao et al.   CELL

Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

(2010) M. P. Chao et al.   Science Translational Medicine

Macrophages as mediators of tumor immunosurveillance

(2010) Siddhartha Jaiswal et al.   TRENDS IN IMMUNOLOGY

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL